Meitav Investment House Ltd. Grows Position in MediWound Ltd. $MDWD

Meitav Investment House Ltd. raised its holdings in MediWound Ltd. (NASDAQ:MDWD) by 825.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,618 shares of the biopharmaceutical company’s stock after purchasing an additional 260,116 shares during the period. Meitav Investment House Ltd.’s holdings in MediWound were worth $5,241,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the period. Rhumbline Advisers lifted its position in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 481 shares in the last quarter. Jane Street Group LLC bought a new position in shares of MediWound in the second quarter worth $295,000. Finally, Marshall Wace LLP bought a new position in shares of MediWound in the second quarter worth $317,000. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on MDWD shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Wednesday, October 8th. Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $33.50.

MediWound Stock Down 6.4%

Shares of NASDAQ MDWD opened at $16.25 on Friday. The stock’s 50-day simple moving average is $18.23 and its two-hundred day simple moving average is $18.32. MediWound Ltd. has a twelve month low of $14.14 and a twelve month high of $22.50. The firm has a market capitalization of $180.21 million, a P/E ratio of -8.55 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.57. The company had revenue of $5.43 million during the quarter, compared to analyst estimates of $6.56 million. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%. As a group, research analysts anticipate that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.